CN116178546A - Multifunctional recombinant antibody and preparation method and application thereof - Google Patents
Multifunctional recombinant antibody and preparation method and application thereof Download PDFInfo
- Publication number
- CN116178546A CN116178546A CN202211255697.8A CN202211255697A CN116178546A CN 116178546 A CN116178546 A CN 116178546A CN 202211255697 A CN202211255697 A CN 202211255697A CN 116178546 A CN116178546 A CN 116178546A
- Authority
- CN
- China
- Prior art keywords
- antibody
- recombinant antibody
- amino acid
- multifunctional
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims abstract description 62
- 102000045309 human NT5E Human genes 0.000 claims abstract description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 239000013604 expression vector Substances 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 6
- 102000056003 human IL15 Human genes 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 239000003124 biologic agent Substances 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 238000001742 protein purification Methods 0.000 claims description 3
- 238000010170 biological method Methods 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102100022464 5'-nucleotidase Human genes 0.000 abstract description 40
- 210000004881 tumor cell Anatomy 0.000 abstract description 24
- 102000003812 Interleukin-15 Human genes 0.000 abstract description 19
- 108090000172 Interleukin-15 Proteins 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 231100000419 toxicity Toxicity 0.000 abstract description 6
- 230000001988 toxicity Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000001588 bifunctional effect Effects 0.000 abstract description 3
- 230000002147 killing effect Effects 0.000 abstract description 3
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 53
- 230000027455 binding Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 239000000243 solution Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 101710120037 Toxin CcdB Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000004008 5'-Nucleotidase Human genes 0.000 description 3
- 108700004024 5'-Nucleotidase Proteins 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 108010057840 ALT-803 Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a multifunctional recombinant antibody and a preparation method and application thereof, and the invention not only provides a monoclonal antibody capable of specifically recognizing human CD73 protein, but also provides a humanized recombinant antibody thereof, and the multifunctional antibody which can recognize human CD73 and has IL15 function can be obtained by further reconstruction on the basis, so that the killing effect of a primary antibody on tumor cells can be effectively enhanced. Meanwhile, the invention also obtains a modified specific CD73 monoclonal antibody-IL 15 bifunctional molecule by introducing a mutated human IgG1 constant region, which can effectively reduce the toxicity of the antibody and improve the safety. The antibody provided by the invention can identify CD73 protein in various tumor cells, further has a killing effect on various tumor cells, and meanwhile, the reconstructed multifunctional recombinant antibody has the advantages of short medicament metabolism period, low toxicity and high safety, and has a huge application prospect.
Description
Technical Field
The invention belongs to the technical field of biology, relates to a multifunctional recombinant antibody, a preparation method and application thereof, and in particular relates to a multifunctional recombinant antibody capable of recognizing CD73 and having an IL15 function and application thereof.
Background
Antibody drugs have become a major component of anticancer drugs at present, but in terms of solid tumors, the efficacy of antibody drugs is still limited, so it is important to find more novel solid tumor antigens, but it is also relatively difficult. For solid tumor treatment, it is important to overcome the improved therapeutic effect by relieving the inhibition of immune effector cells by Tumor Microenvironment (TME). CD73 is a 5-primary nucleotide hydrolase that hydrolyzes extracellular Adenosine Monophosphate (AMP) to adenosine, which is a powerful immunosuppressive molecule that inhibits activation of CD8 positive T cells, thereby helping cancer cells escape T cells "chase-killing", which can be said to be one of the key components of immunosuppressive microenvironment formation in cancer. CD73 is reported to be expressed in many different cancers, including colon, lung, pancreas, ovary, bladder, leukemia, glioma, glioblastoma, melanoma, thyroid, esophageal, prostate, and breast cancers, among others. Furthermore, CD73 expression in cancer is associated with cell proliferation, migration, neovascularization, invasiveness, metastasis, and shorter survival in patients. CD73 activity has also been proposed as a prognostic marker for papillary thyroid cancer. While CD73 has been shown to regulate tumor cell-to-cell and cell-to-matrix interactions, CD73 expression and activity has also been associated with reduced T cell responses and has been proposed to be involved in drug resistance. Thus, CD73 can directly and indirectly regulate the development of cancer, which embodies its potential as a new therapeutic target, and thus inhibition of its activity by regulation and the development of related therapeutic agents are highly desirable.
IL15 is a cytokine expressed by a variety of cells, including monocytes, macrophages, epidermal cells, fibroblasts, etc., but not T lymphocytes. Unlike many other cytokines, IL15 generally does not secrete cells to function, but rather, in combination with IL15 ra localizes to specific cell membranes, thereby stimulating nearby effector cells, principally NK and cd8+ T cells. IL15 is closely related to IL2, and IL15Rα can bind to the common beta/gamma receptor of IL2 after forming a complex, mediating the biological activity. One advantage of IL15 over IL2 in terms of anti-tumor effect is that IL 15/ra does not stimulate Treg proliferation. Currently, there are a number of IL 15-related molecules that are used in the research and development stage to treat malignant tumors. Among the fastest-evolving ones is ALT-803, a complex whose molecule is formed by IL15 and IL15Rα sushi-hFc 1. Several clinical studies have shown that ALT-803 is effective against a variety of tumors including melanoma, but at the same time, serious toxic side effects, mainly including liver function damage, hypotension, fever, etc., occur.
The development of a drug which can kill various cancer cells and has small toxic and side effects has important significance.
Disclosure of Invention
In view of the above problems, an object of the present invention is to provide a monoclonal antibody capable of specifically recognizing CD73 protein, a hybridoma cell secreting the monoclonal antibody; the monoclonal antibody is subjected to humanized transformation to obtain a recombinant antibody; and multifunctional recombinant antibodies capable of recognizing human CD73 protein and having IL15 function.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: a monoclonal antibody capable of recognizing human CD73-ECD protein; the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO:5, the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO: shown at 7.
The invention prepares a mouse-derived monoclonal antibody capable of specifically recognizing human CD73 protein by immunizing mice with recombinant expressed human CD73-ECD protein, which is named as 3E10. The amino acid sequences of the heavy chain variable region and the light chain variable region of the murine monoclonal antibody are obtained through biological analysis.
Furthermore, the invention also claims a recombinant antibody which is obtained by humanizing the monoclonal antibody 3E10, and the amino acid sequence of the heavy chain variable region of the recombinant antibody is shown as SEQ ID NO:16, the amino acid sequence of the light chain variable region of the recombinant antibody is shown as SEQ ID NO: shown at 18.
As a preferred embodiment of the present invention, the heavy chain amino acid sequence of the recombinant antibody is shown in SEQ ID NO:17, the light chain amino acid sequence of the recombinant antibody is shown as SEQ ID NO: 19.
The inventor of the present invention further analyzes the obtained murine monoclonal antibody 3E10 sequence, replaces the CDR region of the human template, recombines the heavy chain variable region with the human IgG1 constant region, recombines the light chain variable region with the human kappa chain constant region, and simultaneously, based on the three-dimensional structure of the antibody, carries out back mutation on embedded residues, residues directly interacted with the CDR region and residues having important influence on the conformation of VL and VH of each antibody, and finally obtains the humanized recombinant antibody, which is named hu3E10. The amino acid sequence, heavy chain amino acid sequence and light chain amino acid sequence of the humanized recombinant antibody hu3E10 heavy chain variable region and light chain variable region are shown in the description.
Further, the present invention also claims a multifunctional recombinant antibody whose heavy chain comprises an antibody functional region that recognizes human CD73, a human IgG1 constant region functional region, an IL15 functional region, and a nonfunctional amino acid fragment for linking the functional regions; the amino acid sequence of the antibody functional region that recognizes human CD73 comprises the heavy chain variable region amino acid sequence of the recombinant antibody.
The IL15 domain recognizes the functional domain of the human IL2/IL15 beta/gamma receptor.
The inventors of the present invention further modified the humanized antibody obtained as described above, and connected the heavy chain sequence of the antibody to a sequence having an IL15 function, thereby further obtaining a recombinant antibody capable of recognizing human CD73 protein and having an IL15 function.
As a preferred embodiment of the invention, the human IgG1 constant region functional domain is a human IgG1 constant region and has the amino acid sequence shown in SEQ ID NO: shown at 8.
More preferably, the human IgG1 constant region functional domain is a mutated human IgG1 constant region having an amino acid sequence as set forth in SEQ ID NO: shown at 24.
The inventor of the invention uses the sequence of the mutant human IgG1 constant region to obtain the multifunctional recombinant antibody with shorter metabolism period, lower toxic and side effects and better safety.
As a preferred embodiment of the invention, the amino acid sequence of the human IL15 functional region is shown in SEQ ID NO: 21.
More preferably, the amino acid sequence of the human IL15 functional region is as set forth in SEQ ID NO: shown at 22.
SEQ ID NO:22 are human IL15Rsushi and human IL15 pass (GGGGS) 6 Ligation forms single chain IL15, i.e., IL15sc.
In a preferred embodiment of the present invention, the non-functional amino acid fragment for linking each functional region in the multifunctional recombinant antibody is a GGGGS repeat.
More preferably, the GGGGS repeat is (GGGGS) 3 。
As a preferred embodiment of the invention, the amino acid sequence of the functional domain of the human IgG1 constant region of the multifunctional recombinant antibody is shown in SEQ ID NO:8, 8; the heavy chain amino acid sequence of the multifunctional recombinant antibody is shown as SEQ ID NO: indicated at 23; the amino acid sequence of the light chain of the multifunctional recombinant antibody is shown as SEQ ID NO: 19.
The invention prepares a multifunctional antibody which can recognize CD73 and has IL15 function and is named SPGL003.
More preferably, the human IgG1 constant region functional domain of the multifunctional recombinant antibody is a mutated human IgG1 constant region, and the amino acid sequence of the mutated human IgG1 constant region is as shown in SEQ ID NO: shown at 24; the heavy chain amino acid sequence of the multifunctional recombinant antibody is shown as SEQ ID NO: 26; the amino acid sequence of the light chain of the multifunctional recombinant antibody is shown as SEQ ID NO: 19.
The multifunctional recombinant antibody prepared by utilizing the preferred multifunctional recombinant antibody sequence comprises a sequence of a mutated human IgG1 constant region, and is named SPGL004; the multifunctional recombinant antibody SPGL004 not only can effectively identify CD73 in various tumor cells and effectively inhibit the growth of various cancer cells, but also has shorter half-life, lower toxicity and good safety.
Further, the invention also claims nucleotide sequences encoding said monoclonal antibodies, or said recombinant antibodies, or said multifunctional recombinant antibodies.
According to the amino acid sequence of the monoclonal antibody, the recombinant antibody or the multifunctional recombinant antibody, the nucleotide sequence of the corresponding coding gene can be obtained.
As a preferred embodiment of the present invention, the heavy chain variable region nucleotide sequence of the monoclonal antibody is shown in SEQ ID NO:4, the nucleotide sequence of the light chain variable region is shown as SEQ ID NO: shown at 6.
Further, the present invention also claims an expression vector comprising the nucleotide sequence.
By means of molecular biology, expression vectors containing the nucleotide sequences can be constructed.
Further, the invention also claims host cells comprising said expression vectors.
By means of cell biology, host cells capable of efficiently expressing the antibody proteins can be constructed using the expression vectors.
Further, the invention also claims the monoclonal antibody, or the recombinant antibody, or the multifunctional recombinant antibody; or the nucleotide sequence, or the expression vector, or the host cell, in the preparation of a biological agent for the treatment of tumors.
Further, the invention also claims a biological agent comprising said monoclonal antibody, or said recombinant antibody, or said multifunctional recombinant antibody; or at least one of said nucleotide sequence, or said expression vector, or said host cell.
Further, the invention also provides a preparation method of the monoclonal antibody or the recombinant antibody or the multifunctional recombinant antibody, which comprises the following steps:
(1) Obtaining an expression vector containing the gene fragment of the monoclonal antibody or the recombinant antibody or the multifunctional recombinant antibody through an artificial synthesis or molecular biological method;
(2) Transfecting the expression vector into cells for protein expression;
(3) The monoclonal antibody or the recombinant antibody or the multifunctional recombinant antibody is obtained through protein purification.
The corresponding antibody can be obtained by respectively constructing expression vectors containing heavy chain or light chain sequences of the antibody, transfecting proper cells for expression and purification.
As a preferred embodiment of the present invention, in the step (1), the expression vector for preparing the gene fragment containing the monoclonal antibody or the recombinant antibody or the multifunctional recombinant antibody by molecular biology is: the heavy or light chain nucleotide sequence of the antibody was inserted into pcdna3.4 expression vector.
As a preferred embodiment of the present invention, in the step (2), the cell for protein expression is an Expi-293F cell.
As a preferred embodiment of the present invention, the Protein purification method in the step (3) is purification by Protein G.
Compared with the prior art, the invention has the following technical effects:
the invention not only prepares a monoclonal antibody capable of specifically recognizing human CD73 protein, but also provides a humanized recombinant antibody thereof. On the basis, the inventor further utilizes the CD73 specific recombinant antibody to prepare the multifunctional recombinant antibody which can not only recognize human CD73, but also has the IL15 function, and can effectively enhance the killing effect of the original antibody on tumor cells. Furthermore, the invention also obtains a modified specific CD73 monoclonal antibody-IL 15 difunctional molecule by introducing a mutated human IgG1 constant region, and the molecule can effectively shorten the metabolism period while maintaining the anti-tumor activity in vivo, thereby reducing the toxic and side effects in vivo and greatly improving the safety. The multifunctional recombinant antibody provided by the invention can identify CD73 in various tumor cells, and has a huge application prospect.
Drawings
FIG. 1 results of binding of antibody 3E10 to human CD73.
FIG. 2 results of antibody 3E10 inhibiting the activity of NCI-H1975 cell CD73 enzyme.
FIG. 3 results of binding of antibody 3E10 to mouse, cynomolgus monkey CD73 antigen.
FIG. 4 results of binding of human antibody hu3E10 to human CD73
FIG. 5 results of inhibition of tumor cell membrane CD73 enzymatic activity by human antibody hu3E10.
FIG. 6 results of binding of multifunctional recombinant antibodies SPGL003, SPGL004 to human CD73.
FIG. 7 results for the simultaneous binding of CD73 and CD122/132 by each set of antibodies.
FIG. 8 multifunctional recombinant antibody SPGL003, SPGL004 inhibited tumor cell membrane CD73 enzyme activity.
FIG. 9 results of stimulation of CTLL2 cell proliferation by multifunctional recombinant antibodies SPGL003, SPGL004; a is the detection result of SPGL003 and SPGL004, and B is the detection result of IL 2.
FIG. 10 shows the results of the change in volume of the mouse colorectal cancer cell MC38 engraftment tumor of each group over time.
FIG. 11 shows the results of the change in the volume of human lung cancer cell H1975 transplants over time.
FIG. 12 results of inhibition of human breast cancer cell JIMT-1 engraftment by the multifunctional recombinant antibody SPGL004 in combination with HER2 mab.
FIG. 13 in vivo metabolism of multifunctional recombinant antibodies SPGL003 and SPGL004 in huFcRn transgenic mice.
FIG. 14 results of flow-through detection of SPGL004 binding to various tumor cells CD73.
FIG. 15 multifunctional recombinant antibody SPGL004 placed on 0 periprotein.
FIG. 16 multifunctional recombinant antibody SPGL004℃placed at 5 periprotein.
FIG. 17 multifunctional recombinant antibody SPGL004 placed at 37℃for 5 periprotein.
Detailed Description
For a better description of the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to the accompanying drawings and specific embodiments.
EXAMPLE 1 preparation of monoclonal antibodies and hybridomas
1) Antigen immunized mice: human CD73-ECD protein (commercially available from Beijing Bai Pogostemon Co., acro BIOSYSTEMS, SEQ ID NO: 1) was used for recombinant expression.
On the first day, after fully mixing the soluble human CD73-ECD protein with Freund's complete adjuvant (CFA, sigma Co.) emulsion, balb/c mice were subcutaneously injected (50. Mu.g/mouse); after fully mixing the soluble human CD73-ECD protein with Freund's incomplete adjuvant emulsion (IFA, sigma Co.) on days 14 and 36, balb/c mice were subjected to subcutaneous booster immunization (50. Mu.g/mouse); on day 50, the mice spleen was taken for fusion experiments 3-4 days after intraperitoneal injection of human CD73-ECD protein 50 μg/mouse challenge.
2) Preparation and selection of hybridomas:
the spleen cells of the mice were fused with myeloma cells SP2/0 of the mice by PEG (PEG 1450, sigma company) method using conventional hybridoma technique 3-4 days after the last impact immunization of the mice. The fused cells were suspended uniformly in complete medium, i.e. RPMI1640 and DMEM F12 medium 1: 1% glutamine (Gibco Co.), 1% sodium pyruvate (Gibco Co.), 1% MEM-NEAA (minimum minimal medium-non-essential amino acid solution, gibco Co.), 1% penicillin-streptomycin (Gibco Co.), 50. Mu.M beta-mercaptoethanol (Gibco Co.) and 20% FBS (Gibco Co.). Press 10 5 Individual cells/100 μl/well were plated in 96-well plates overnight. The next day, 100. Mu.L of complete medium containing 2 XHAT (Sigma Co.) was added to each well, and the volume of medium in the 96-well plate was 200. Mu.L/well (containing 1 XHAT). After 7-12 days, supernatants were harvested and hybridoma wells positive for human CD73-ECD protein binding activity were screened by indirect enzyme-linked immunosorbent assay (ELISA).
Wherein, the method for screening the hybridoma holes positive for the activity of the human CD73-ECD protein by using the indirect ELISA method comprises the following steps: recombinant human CD73-ECD protein was diluted to 1. Mu.g/mL with coating solution (50 mM carbonate coating buffer, pH 9.6), 100. Mu.L/well was added to the ELISA plate and coated overnight at 4 ℃. PBST plate washing 3 times, adding 200 u L/hole blocking solution (2%BSA-PBST), 37 ℃ after 1h PBST plate washing 1 time for use. The collected hybridoma supernatants were sequentially added to the blocked ELISA plates at 100. Mu.L/well and left at 37℃for 1 hour. PBST plates were washed 3 times, HRP-labeled goat anti-mouse IgG secondary antibody (purchased from Abcam, cat. No. ab 6789) was added and left at 37℃for 30min; after PBST washing the plate for 5 times, the residual liquid drops are beaten as much as possible on the absorbent paper, 100 mu L TMB (KPL company) is added into each hole, and the plate is placed for 5 minutes at room temperature (20+/-5 ℃) in a dark place; 50 mu L of 2M H are added to each well 2 SO 4 Stopping the substrate reaction by using a stopping solution, reading an OD value at 450nm of an enzyme-labeled instrument, and analyzing the human CD73-ECD egg of the antibody to be detected and the target antigenWhite binding ability.
Amplifying and screening the obtained hybridoma cell strain in a serum-containing complete culture medium, centrifuging and changing the solution to a serum-free culture medium (SFM culture medium) to ensure that the cell density is 1-2 multiplied by 10 7 personal/mL, at 5% CO 2 Culturing at 37deg.C for 2 weeks, centrifuging to obtain culture supernatant, and purifying by Protein G affinity chromatography to obtain mouse anti-human CD73-ECD Protein monoclonal antibody, designated 3E10.
Example 2ELISA assay for binding Activity of 3E10 to human CD73
The experimental steps are as follows: human CD73 was pre-coated and diluted with coating solution (50 mM carbonate coating buffer, pH 9.6) to 5. Mu.g/mL plates overnight at 4 ℃; then the mixture is sealed by 5% skimmed milk powder at 37 ℃ for 2 hours. PBST plate was washed 3 times, and the antibody to be tested diluted with 1% BSA-PBST gradient was sequentially added to the blocked ELISA plate, 100. Mu.L/well, and left at 37℃for 1h. PBST plates were washed 3 times, HRP-labeled goat anti-mouse IgG secondary antibody (available from Millipore under the accession number AP 181P) was added, and left at 37℃for 30min; after PBST washing the plate for 3 times, the residual liquid drops are beaten as much as possible on the absorbent paper, 100 mu L TMB (KPL company) is added into each hole, and the plate is placed for 5min at room temperature (20+/-5 ℃) in a dark place; 50 mu L of 2M H are added to each well 2 SO 4 The stopping solution stops the substrate reaction, the OD value is read at 450nm of the enzyme-labeled instrument, and the binding capacity of the antibody to be detected and the target antigen human CD73 is analyzed.
The experimental results are shown in FIG. 1. As can be taken from FIG. 1, antibody 3E10 binds to EC of CD73-ECD 50 29.83ng/mL, i.e., 0.20nM; it was demonstrated that antibody 3E10 had good binding activity to CD 73-ECD.
EXAMPLE 3 murine antibody 3E10 inhibits NCI-H1975 cell CD73 enzymatic Activity
CD73 expressed by tumor cells has enzymatic activity and can decompose AMP into Ado. AMP can inhibit the chemiluminescent reaction caused by ATP, but Ado does not. Thus, the activity of CD73 can be detected by detecting the consumption of AMP, thereby detecting the inhibition of the activity of CD73 enzyme by monoclonal antibodies.
The experimental steps are as follows: human tumor cells NCI-H1975 were seeded into 96-well cell culture plates (Corning, cat # 3599) at 30000 cells/well in CO 2 Cell incubator culture overnight, next day, suction and discard cultureSupernatant, add to-be-detected mab or control mab, 50 μl/well, serial dilutions (starting at 10000ng/mL, 3-fold ratio dilution for 10 gradients, minimum concentration to 0.5 ng/mL), incubate for 30min at 37 ℃, add to 800 μl/well of 800 μM AMP (Sigma, cat#a1752) solution in serum-free medium, incubate for 3 hours at 37 ℃. mu.L/well of the cell reaction solution was pipetted into a fluorescence detection plate (White Opaque 96-well Microplate, perkinelmer, cat # 6005290), then 25. Mu.L/well of 80. Mu.M ATP solution prepared without serum medium was added, 50. Mu.L/well CTG solution (CellTiter Glo, promega, cat#G 7573) was added, and after incubation at room temperature for 5 minutes, the fluorescence value was detected by a chemiluminescent detector (BioTech).
The experimental results are shown in FIG. 2. IC of antibody 3E10 inhibiting CD73 enzymatic activity of tumor cell NCI-H1975 50 39.89ng/mL, i.e., 0.27nM.
Example 4 determination of Cross Activity of antibody 3E10 with mouse, cynomolgus monkey CD73 antigen
Experimental procedure similar to example 2, human CD73-ECD was replaced with mouse CD73-ECD (amino acid sequence shown as SEQ ID NO: 2) and cynomolgus monkey CD73-ECD (amino acid sequence shown as SEQ ID NO: 3), respectively, both purchased from Beijing Baiposis corporation. The binding capacity of antibody 3E10 to the mouse, cynomolgus monkey CD73 antigen was determined.
The experimental results are shown in FIG. 3. As can be seen from FIG. 3, antibody 3E10 binds well to cynomolgus CD73 protein, EC 50 Is 33.63ng/mL, i.e., 0.22nM, comparable to human CD73 (EC 50 0.20 nM); but mab 3E10 did not bind to mouse CD73.
EXAMPLE 5 preparation of humanized antibody hu3E10
The heavy chain variable region and the light chain variable region of hybridoma 3E10 were obtained by a molecular biology-related method, and a chimeric antibody was further constructed.
RNA from 3E10 hybridoma cells was extracted by Trizol and mRNA was reverse transcribed to obtain cDNA, which was then used as a template to carry out PCR with heavy and light chain degenerate primers of murine antibodies, respectively (Antibody Engineering, volume 1,Edited by Roland Kontermann and Stefan D ubel, combined primer sequences from page 323), the PCR products obtained were sequenced and analyzed by kabat database to determine the variable region sequence of murine antibodies. The relevant sequence information is as follows:
the gene sequence of the 3E10 heavy chain variable region has the total length of 366bp, codes 122 amino acid residues and has the nucleotide sequence shown in SEQ ID NO:4, the amino acid sequence is shown as SEQ ID NO:5 is shown in the figure; the gene sequence of the 3E10 light chain variable region has the total length of 333bp and codes 111 amino acid residues, and the nucleotide sequence is shown as SEQ ID NO:6, the amino acid sequence is shown as SEQ ID NO: shown at 7.
The amino acid sequences of the light chain variable region and the heavy chain variable region of the 3E10 antibody were analyzed to determine 3 Complementarity Determining Regions (CDRs) and 4 Framework Regions (FRs) of the murine antibody according to the Kabat rule. The amino acid sequence of the 3E10 heavy chain complementarity determining region is HCDR1: GYSSFTSYW (SEQ ID NO: 10), HCDR2: IYPHGNSDT (SEQ ID NO: 11), HCDR3: TREGSKGYDVWYFAV (SEQ ID NO: 12), the amino acid sequence of the light chain complementarity determining region being LCDR1: KSVSTSGYSY (SEQ ID NO: 13), LCDR 2:LASLNLES (SEQ ID NO: 14) and LCDR3: QHSRELPFT (SEQ ID NO: 15).
And selecting a humanized template which is best matched with the FR region of each murine antibody from a Germline database. Then the CDR region of the murine antibody is transplanted onto the selected humanized template, the CDR region of the humanized template is replaced, the heavy chain variable region is recombined with the human IgG1 constant region (SEQ ID NO: 8), the light chain variable region is recombined with the human kappa chain constant region (SEQ ID NO: 9), and on the basis of the three-dimensional structure of the antibody, the embedded residues, the residues directly interacted with the CDR region and the residues having important influence on the conformation of the VL and VH of each antibody are subjected to back mutation, so that the humanized antibody hu3E10 is finally obtained.
The humanized antibody hu3E10 (the heavy chain variable region amino acid sequence is shown as SEQ ID NO:16, the heavy chain amino acid sequence is shown as SEQ ID NO:17, the light chain variable region amino acid sequence is shown as SEQ ID NO:18, and the light chain amino acid sequence is shown as SEQ ID NO: 19).
The heavy chain and light chain of humanized antibody hu3E10 are respectively constructed to pcDNA3.4 expression vectors, an Expi-293F cell is transfected, humanized antibody hu3E10 is obtained through Protein G purification, and the molecular weight of each antibody is determined to be correct and the purity is more than 95 percent through SDS-PAGE electrophoresis and SEC-HPLC.
EXAMPLE 6ELISA method for determining the binding Activity of humanized antibody hu3E10 to human CD73
Experimental method referring to example 2, the binding activity of humanized antibody hu3E10 to human CD73 was measured and the experimental results are shown in fig. 4.
The experimental results are shown in FIG. 4, which shows the EC of humanized antibody hu3E10 binding to human CD73 50 Is 5.44ng/mL, i.e., 0.04nM, significantly lower than antibody 3E10 (its EC 50 29.83ng/mL, i.e., 0.20nM, as shown in example 2). It was demonstrated that humanized antibody hu3E10 had good binding activity to human CD73.
EXAMPLE 7 humanized antibody hu3E10 inhibition of tumor cell membrane CD73 enzymatic Activity assay
Experimental method referring to example 3, the effect of the humanized antibody hu3E10 on inhibiting the CD73 enzyme activity of tumor cell membrane was measured, and the experimental result is shown in fig. 5.
As can be seen from FIG. 5, humanized antibody hu3E10 can inhibit the enzymatic activity of tumor cell CD73 with high efficiency, IC 50 27.81ng/mL, i.e., 0.19nM, activity higher than that of mouse monoclonal antibody 3E10 (IC 50 0.27 nM). The humanized antibody hu3E10 was shown to inhibit tumor cell membrane CD73 enzymatic activity.
Example 8 preparation of multifunctional recombinant antibodies
1. Functional region of human IL 15: human IL15Rsushi (its amino acid sequence SEQ ID NO: 20) was passed through (GGGGS) with human IL15 (its amino acid sequence SEQ ID NO: 21) 6 Ligation forms single chain IL15, i.e. IL15sc, the amino acid sequence of which SEQ ID NO: shown at 22.
2. Antibody functional region that recognizes human CD 73:
(1) heavy chain of SPGL 003: the hu3E10 heavy chain sequence (amino acid sequence shown as SEQ ID NO: 17) was passed through (GGGGS) with human IL15sc sequence 3 Splicing to form a heavy chain of SPGL003 (the amino acid sequence is shown as SEQ ID NO: 23);
(2) heavy chain of SPGL 004: the hu3E10 heavy chain VH sequence (amino acid sequence shown as SEQ ID NO: 16) was ligated to a mutated human IgG1 constant region (amino acid sequence shown as SEQ ID NO: 24) to form a hu3E10mu heavy chain (amino groupThe acid sequence is shown in SEQ ID NO: 25). hu3E10mu heavy chain and human IL15sc sequence pass (GGGGS) 3 Splicing to form the heavy chain of SPGL004 (the amino acid sequence is shown as SEQ ID NO: 26).
(3) The light chain is identical to the light chain sequence of hu3E10 (the amino acid sequence is shown in SEQ ID NO: 19).
3. Preparation of multifunctional recombinant antibodies
The heavy chain and the light chain of SPGL003 (or the heavy chain and the light chain of SPGL 004) are transfected into an Expi-293F cell in a cotransfection way, and the multifunctional recombinant antibody SPGL003 (or the multifunctional recombinant antibody SPGL 004) can be obtained through Protein G purification. The molecular weight of each expressed antibody was determined to be correct by SDS-PAGE electrophoresis and SEC-HPLC, and the purity of the antibody was >95%. The prepared multifunctional antibody is quantitatively packaged and frozen at-80 ℃ for standby.
EXAMPLE 9 multifunctional recombinant antibody SPGL004 binds CD73-ECD
Experimental methods referring to example 2, the binding activity of the multifunctional recombinant antibodies SPGL003 and SPGL004, respectively, to human CD73-ECD was measured, and the experimental results are shown in FIG. 6.
As can be seen from FIG. 6, SPGL004 and SPGL003 bind to EC of human CD73-ECD 50 31.42ng/mL and 34.26ng/mL, i.e., 0.16nM and 0.18nM, respectively, are consistent with hu3E10 (0.20 nM, as shown in example 6), demonstrating that hu3E10 does not affect binding to CD73 after forming a bifunctional molecule with IL15, nor does the mutation of IgG1 in the bifunctional molecule affect binding to CD73.
EXAMPLE 10 multifunctional recombinant antibody SPGL004 simultaneously binds CD73-ECD and CD122/132
The experimental method comprises the following steps: pre-coating human CD73-ECD protein, diluting to 2 μg/mL coating plate with coating solution (50 mM carbonate coating buffer, pH 9.6), 4 ℃ overnight; sealing with 5% skimmed milk powder at 37deg.C for 2 hr; PBST plate was washed 3 times, and the antibody to be tested was diluted to 1. Mu.g/mL with a 1% BSA-PBST gradient, and the blocked ELISA plate was added at 100. Mu.L/well and left at 37℃for 1h. PBST plates were washed 3 times, gradient diluted biotin-labeled CD122/132 (from Beijing Baipessary Co.) was added, 37℃for 1 hour, and after 3 times PBST plates were washed, diluted HRP-labeled SA (Pierce Co.) was added, and left at 37℃for 30 minutes; after 3 washes of PBST plates, inThe residual liquid drop is beaten as much as possible on the absorbent paper, 100 mu L TMB (KPL company) is added into each hole, and the mixture is placed for 5min at room temperature (20+/-5 ℃) in a dark place; 50 mu L of 2M H are added to each well 2 SO 4 The stop solution stops the substrate reaction, the OD value is read at 450nm of the enzyme label instrument, and the binding capacity of the antibody to be detected and human CD122/132 is analyzed.
The experimental results are shown in FIG. 7. As can be seen in FIG. 7, antibodies SPGL004 and SPGL003 bind to the EC of human CD122/132 protein under the present experimental conditions 50 15.85ng/mL and 16.84ng/mL, i.e., 0.08nM and 0.09nM, respectively, demonstrating good activity of both multifunctional recombinant antibodies SPGL004 and SPGL003 in binding both CD73 and CD 122/132; in contrast, the control hu3E10 antibody, while capable of binding CD73, was unable to bind CD122/132.
EXAMPLE 11 determination of the Activity of multifunctional recombinant antibodies SPGL003, SPGL004 against tumor cell membrane CD73 enzyme
Experimental method referring to example 3, the effect of the multifunctional recombinant antibodies SPGL004 and SPGL003 on inhibiting the activity of tumor cell membrane CD73 enzyme was determined. The experimental results are shown in FIG. 8.
As can be seen from FIG. 8, antibodies SPGL004 and SPGL003 inhibit the CD73 enzyme activity of tumor cell NCI-H1975 50 50.99ng/mL and 53.08ng/mL, respectively, i.e., 0.27nM and 0.28nM, the enzyme inhibition activity was slightly weaker than that of hu3E10 (EC 50 0.19 nM).
EXAMPLE 12 multifunctional recombinant antibodies SPGL003, SPGL004 stimulated CTLL2 cell proliferation
The experimental method comprises the following steps: CTLL2 cells were diluted to 5X 10 in 1640 medium containing 10% FBS 4 Per mL,100 μl/well was added to the cell culture plate. IL2 is diluted to 30ng/mL by 1640 culture solution containing 10% FBS, and after the dilution of 3 times of the culture solution is divided into 8 gradients, the culture plates containing CTLL2 cells are respectively added; SPGL004 and SPGL003 were diluted to 5000ng/mL in 1640 medium containing 10% FBS, and after 3-fold specific dilution, 8 gradients were added to each of the plates containing CTLL2 cells; CO 2 After 72 hours of incubation in the cell incubator, the relative cell numbers of each well were determined with CCK8 and EC was calculated 50 The activity of the sample was judged. The experimental results are shown in FIG. 9.
As can be seen from FIG. 9A, the multifunctional recombinant antibodies SPGL004 and SPGL003Can stimulate proliferation of CTLL2 cells, EC 50 104.8ng/mL and 99.3ng/mL, i.e., 0.55nM and 0.52nM, respectively, indicate that SPGL004 has biological activity consistent with SPGL003. As a control, as can be taken from FIG. 9B, EC of IL2 50 0.75ng/mL, i.e., 0.049nM.
EXAMPLE 13 the multifunctional recombinant antibody SPGL004 showed significantly reduced toxicity in mice compared to SPGL003
The experimental method comprises the following steps: the multifunctional recombinant antibodies SPGL004 and SPGL003 were injected into the abdominal cavity of C57BL/6 mice (Vetong Lihua Co.) 3 times on days 1, 3 and 5, the injection volume was 0.2 mL/time, SPGL004 and SPGL003 were administered at doses of 0.5mg/kg, 1mg/kg, 2mg/kg and 4mg/kg, the death of the experimental mice was observed every day, and the control group was administered with the same volume of PBS. The results are shown in Table 1.
Table 1 survival of experimental animals in each dose group
| Antibodies to | 0.5mg/kg | 1.0mg/kg | 2.0mg/kg | 4.0mg/ |
| SPGL003 | ||||
| 100％ | 50％ | 0％ | 0 | |
| SPGL004 | ||||
| 100％ | 100％ | 100％ | 10％ |
As shown in table 1, on day 7 of the experiment, all experimental animals in the SPGL003 samples in the 4.0mg/kg group and the 2.0mg/kg group died (survival rate 0%); the 1.0mg/kg group still had 50% of the experimental animals died, while the 0.5mg/kg group had no experimental animals died; SPGL004 sample 4.0mg/kg showed 90% of the experimental animal deaths, but none of the remaining dose groups had the experimental animal deaths. These results demonstrate that SPGL004 toxicity to experimental mice is significantly reduced following Fc mutation.
EXAMPLE 14 multifunctional recombinant antibody SPGL004 inhibits mouse colorectal cancer cell MC38 transplantation tumor growth
The experimental method comprises the following steps: collecting in vitro cultured mouse colon cancer MC38 cells, and regulating cell suspension concentration to 1×10 7 cells/mL. Under sterile conditions, 100. Mu.L of MC38 cell suspension was inoculated subcutaneously into the right flank of C57BL/6 mice. The diameter of the transplanted tumor is measured by a vernier caliper for subcutaneous transplantation of the mouse, and the average tumor volume grows to 100-200mm 3 Animals were then randomly grouped, 6 per group. SPGL004 was administered at 1.0mg/kg, 0.5mg/kg, SPGL003 was administered at 0.5mg/kg, 0.25mg/kg, and the same amount of PBS was administered in the control group, 3 times per week by intraperitoneal injection, and a volume of 0.2 mL/time for 2 weeks. Throughout the experiment, the diameter of the transplanted tumor was measured 3 times per week, and the mice were weighed. The calculation formula of Tumor Volume (TV) is (wherein a, b represent length, width respectively):
TV＝1/2×a×b2。
from the results of the measurements, the relative tumor volume (relative tumor volume, RTV) is calculated as 0 The resulting tumor volumes were measured at d0 for group dosing; v (V) t Tumor volume at each measurement):
RTV＝V t /V 0 。
the evaluation index of the antitumor activity is the relative tumor proliferation rate T/C (%), and the calculation formula is as follows (wherein TRTV: treatment group RTV; CRTV: negative control group RTV):
T/C(％)＝(TRTV/CRTV)×100；
tumor inhibition rate TGI (%) =100-T/C (%).
The measurement results are shown in FIG. 10. As can be seen from FIG. 10, SPGL004 and SPGL003 both show strong antitumor activity, the TGI of SPGL003 at doses of 0.5mg/kg and 0.25mg/kg was 60.6% and 22.9%, respectively, and the TGI of SPGL004 at doses of 1.0 and 0.5mg/kg was 72.2% and 46.1%, respectively.
Referring to example 13, SPGL003 showed lethal toxicity at 1.0mg/kg dose and SPGL004 showed lethal toxicity at 4.0mg/kg dose, it was demonstrated that SPGL004 containing Fc mutation had significantly improved safety while not affecting antitumor activity in vivo.
EXAMPLE 15 multifunctional recombinant antibody SPGL004 inhibits growth of human lung cancer cell NCI-H1975 graft tumor in nude mice
The experimental method comprises the following steps: human lung cancer NCI-H1975 cells cultured in vitro were collected and the cell suspension concentration was adjusted to 8X 10 7 cells/mL. Under sterile conditions, 100 μl of the cell suspension was inoculated subcutaneously into the right flank of nude mice. After tumor cells form solid tumor under the skin of mouse, measuring the diameter of transplanted tumor with vernier caliper, and growing until the average tumor volume reaches 100-200mm 3 Animals were then randomly grouped. The multifunctional recombinant antibody SPGL004 was administered 3 times per week and 6 times per week at doses of 1.0mg/kg, 0.3mg/kg and 0.1 mg/kg. Throughout the experiment, the diameter of the transplanted tumor was measured 2 times per week while weighing the mice. The procedure is as in example 14. The results are shown in FIG. 11.
As can be seen from fig. 11, SPGL004 exhibited strong antitumor activity in human lung cancer cells. SPGL004 had TGI of 59.5%, 58.3% and 44.3% at doses of 1.0mg/kg, 0.3mg/kg and 0.1mg/kg, respectively.
EXAMPLE 16 multifunctional recombinant antibody SPGL004 in combination with HER2 mab inhibit growth of human breast cancer cell JIMT-1 graft tumor in nude mice
The experimental method comprises the following steps: collecting in vitro cultured human breast cancer JIMT-1 cells, and adjusting cell suspension concentration to 8×10 7 cells/mL. In sterile stripsUnder the control, 100 μl of the cell suspension was inoculated subcutaneously in the right flank of nude mice. After tumor cells form solid tumor under the skin of mouse, measuring the diameter of transplanted tumor with vernier caliper, and growing until the average tumor volume reaches 50-100mm 3 Animals were then randomly grouped. The single drug group HER2 mab (trastuzumab) was administered at a dose of 20mg/kg, and the combination group was given 6 times per week by fixed doses of 20mg/kg trastuzumab in combination with 1.0mg/kg and 0.3mg/kg SPGL004, respectively. Throughout the experiment, the diameter of the transplanted tumor was measured 2 times per week while weighing the mice. The procedure is as in example 14. The results are shown in FIG. 12.
As can be seen from fig. 12, the TGI of Qu Tuo bead single drug was 55.3%, the TGI of the trastuzumab with 1.0mg/kg and 0.3mg/kg dose of SPGL004 was 90.3% and 71.7%, respectively, significantly higher than Qu Tuo bead single drug, demonstrating that SPGL004 and Qu Tuo beads have good synergistic antitumor effect.
EXAMPLE 17 in vivo metabolism of multifunctional recombinant antibodies SPGL003 and SPGL004 in huFcRn transgenic mice
The experimental method comprises the following steps: the pharmacokinetics of SPGL003 and SPGL004 were determined using human FcRn transgenic mice. 8 mice were divided into two groups, and SPGL003 and SPGL004 were intraperitoneally injected at a dose of 1mg/kg, and blood was collected after 2 hours, 6 hours, 24 hours, 48 hours and 72 hours, to obtain serum. After the serum was properly diluted, the blood concentration was measured by ELISA, and the method was basically the same as in example 11. The results are shown in FIG. 13.
As can be seen from fig. 13, fc-mutated SPGL004 significantly accelerated metabolism in human FcRn transgenic mice compared to Fc-wild type SPGL003, with half-lives of 9 hours and 22 hours, respectively, differing significantly.
EXAMPLE 18SPGL004 detects the expression of CD73 by multiple tumor cells
The binding force of SPGL004 to various human tumor cells was determined by flow cytometry fluorescence sorting (Fluorescence activated Cell Sorting, FACS).
In vitro culture of various tumor cells, 100. Mu.L of SPGL004 at a concentration of 2000ng/mL was used as primary antibody, respectively, in combination with 1X 10 suspended in 100. Mu.L of RPMI-1640 serum-free medium (available from Gibco Co., ltd., cat. No. 22400089) 5 Fine tumor of individualCells were incubated at 4℃for 1h, cells were washed twice with PBS to remove unbound SPGL004, and then incubated with 100. Mu.L, 2. Mu.g/mL, alexa Fluor 488-labeled anti-human IgG fluorescent secondary antibody (available from Thermo, invitrogen, cat. No. A11013) at 4℃for 30min, cells were washed twice with PBS to remove unbound secondary antibody, and finally resuspended in 100. Mu.L of PBS, the binding affinity of SPGL004 to various cells was determined by flow cytometry, and the resulting MFI values were compared to the MFI values of the control group (not incubated SPGL 004), with the ratio indicating the binding strength of SPGL 004.
As can be seen from fig. 14, SPGL004 can bind to various human lung cancer cells (H1975, calu-3, a549, H322, H292), to human breast cancer cells (JIMT-1), to human kidney cancer cells (a 498), to human skin cancer cells (a 431), indicating that the various tumors described above may become indications for SPGL 004.
Example 19SPGL004 stability detection
And detecting the change of the purity of the SPGL004 after the SPGL004 is placed for different times by adopting a molecular sieve high performance liquid chromatography (SEC-HPLC), and examining the stability of the SPGL 004.
The experimental method comprises the following steps: the reaction was performed on an HPLC Ultimate 3000 (Thermo company) chromatograph using a TSKgel G3000SWXL column (TSK company). The mobile phase was measured as PBS (pH 7.4), constant flow rate 0.8mL/min, and loading was 100. Mu.g/100. Mu.L. The purity was expressed by calculating the content (%) of the target protein in the total protein using the 280nM absorption peak integration method. The results are shown in fig. 15, 16 and 17.
As can be seen from fig. 15, 16 and 17, SPGL004 had a purity of 89.7% in PBS solution for 0 week, a purity of 87.8% after 5 weeks at 4 ℃ and a change rate <3%; after 5 weeks at 37 ℃, the purity is 87.6%, and the change rate is <3%, which shows that SPGL004 is stable in PBS buffer solution under the conditions of 4 ℃ and 37 ℃, and the SPGL004 has good stability.
Finally, it should be noted that the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made to the technical solution of the present invention without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. A monoclonal antibody capable of recognizing human CD73-ECD protein; the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO:5, the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO: shown at 7.
2. A recombinant antibody, characterized in that the recombinant antibody is obtained by humanizing the monoclonal antibody of claim 1, and the amino acid sequence of the heavy chain variable region of the recombinant antibody is shown in SEQ ID NO:16, the amino acid sequence of the light chain variable region of the recombinant antibody is shown as SEQ ID NO: shown at 18.
3. A multifunctional recombinant antibody, characterized in that the heavy chain of the multifunctional recombinant antibody comprises an antibody functional region which recognizes human CD73, a human IgG1 constant region functional region, a functional region of human IL15, and a nonfunctional amino acid fragment for linking the functional regions; the amino acid sequence of the antibody functional region that recognizes human CD73 comprises the heavy chain variable region amino acid sequence of the recombinant antibody of claim 2.
4. The multifunctional recombinant antibody according to claim 3, wherein the human IgG1 constant region functional region is a mutated human IgG1 constant region having the amino acid sequence as set forth in SEQ ID NO: shown at 24; the heavy chain amino acid sequence of the multifunctional recombinant antibody is shown as SEQ ID NO: 26; the amino acid sequence of the light chain of the multifunctional recombinant antibody is shown as SEQ ID NO: 19.
5. Nucleotide sequences encoding the monoclonal antibody of claim 1, or the recombinant antibody of claim 2, or the multifunctional recombinant antibody of claim 3 or 4.
6. An expression vector comprising the nucleotide sequence of claim 5.
7. A host cell comprising the expression vector of claim 6.
8. The monoclonal antibody of claim 1, or the recombinant antibody of claim 2, or the multifunctional recombinant antibody of claim 3 or 4; use of a nucleotide sequence according to claim 5, an expression vector according to claim 6, or a host cell according to claim 7 for the preparation of a biological agent for the treatment of a tumor.
9. A biologic comprising the monoclonal antibody of claim 1, or the recombinant antibody of claim 2, or the multifunctional recombinant antibody of claim 3 or 4; or a nucleotide sequence according to claim 5, or an expression vector according to claim 6, or a host cell according to claim 7.
10. The method for producing a monoclonal antibody according to claim 1 or a recombinant antibody according to claim 2 or a multifunctional recombinant antibody according to claim 3 or 4, comprising the steps of:
(1) Obtaining an expression vector containing the gene fragment of the monoclonal antibody or the recombinant antibody or the multifunctional recombinant antibody through an artificial synthesis or molecular biological method;
(2) Transfecting the expression vector into cells for protein expression;
(3) The monoclonal antibody or the recombinant antibody or the multifunctional recombinant antibody is obtained through protein purification.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211255697.8A CN116178546A (en) | 2022-10-13 | 2022-10-13 | Multifunctional recombinant antibody and preparation method and application thereof |
| PCT/CN2022/141440 WO2024077774A1 (en) | 2022-10-13 | 2022-12-23 | Multifunctional recombinant antibody, and preparation method and use therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211255697.8A CN116178546A (en) | 2022-10-13 | 2022-10-13 | Multifunctional recombinant antibody and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116178546A true CN116178546A (en) | 2023-05-30 |
Family
ID=86441008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211255697.8A Pending CN116178546A (en) | 2022-10-13 | 2022-10-13 | Multifunctional recombinant antibody and preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116178546A (en) |
| WO (1) | WO2024077774A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110214147A (en) * | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15R α heterodimer FC- fusion protein |
| CN110240654A (en) * | 2018-03-07 | 2019-09-17 | 复旦大学 | In conjunction with the antibody-drug conjugates of CD73 |
| CN112513070A (en) * | 2018-02-28 | 2021-03-16 | 辉瑞公司 | IL-15 variants and uses thereof |
| CN113135996A (en) * | 2019-12-09 | 2021-07-20 | 启愈生物技术(上海)有限公司 | Bispecific antibody and application thereof |
| CN113260380A (en) * | 2018-12-18 | 2021-08-13 | 健玛保 | Methods of producing heterodimeric antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112513089A (en) * | 2018-11-12 | 2021-03-16 | 江苏恒瑞医药股份有限公司 | anti-CD 73 antibody, antigen binding fragment thereof and application |
| CN110330566A (en) * | 2019-06-11 | 2019-10-15 | 南京华岩生物技术有限公司 | A kind of immunoglobulin that the bispecific with dual variable domains combines |
| CN112300279A (en) * | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | Methods and compositions directed to anti-CD 73 antibodies and variants |
| EP4025605A1 (en) * | 2019-09-06 | 2022-07-13 | Symphogen A/S | Anti-cd73 antibodies |
-
2022
- 2022-10-13 CN CN202211255697.8A patent/CN116178546A/en active Pending
- 2022-12-23 WO PCT/CN2022/141440 patent/WO2024077774A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110214147A (en) * | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15R α heterodimer FC- fusion protein |
| CN112513070A (en) * | 2018-02-28 | 2021-03-16 | 辉瑞公司 | IL-15 variants and uses thereof |
| CN110240654A (en) * | 2018-03-07 | 2019-09-17 | 复旦大学 | In conjunction with the antibody-drug conjugates of CD73 |
| CN113260380A (en) * | 2018-12-18 | 2021-08-13 | 健玛保 | Methods of producing heterodimeric antibodies |
| CN113135996A (en) * | 2019-12-09 | 2021-07-20 | 启愈生物技术(上海)有限公司 | Bispecific antibody and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024077774A1 (en) | 2024-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113402610B (en) | B7H3 monoclonal antibodies and medical application thereof | |
| JP2019517773A (en) | Anti-LAG-3 antibody | |
| JP5723270B2 (en) | Anti-cadherin antibody | |
| JP2020536109A (en) | Recovery of T cell activity by CD39 / CD73 axis | |
| WO2012176765A1 (en) | Anti-human p-cadherin (cdh3) recombinant antibody | |
| WO2003099205A2 (en) | Treatment of renal carcinoma using antibodies against the egfr | |
| EP3431504B1 (en) | Anti-phospholipase d4 antibody | |
| CN110382533A (en) | Specifically bind the antibody and application thereof of CD66c | |
| WO2017065493A1 (en) | Anti-cd43 antibody and use thereof for cancer treatment | |
| JP7165855B2 (en) | Use for prevention and treatment of myeloid-derived suppressor cell-related diseases | |
| JP2022514786A (en) | MUC18-specific antibody | |
| CN110291107B (en) | Monoclonal antibodies targeting unique sialylated cancer-related epitopes of CD43 | |
| CN114616245B (en) | anti-CD 38 antibody and application thereof | |
| CN116178546A (en) | Multifunctional recombinant antibody and preparation method and application thereof | |
| WO2024077775A1 (en) | Multifunctional recombinant antibody, preparation method therefor, and use thereof | |
| WO2024077777A1 (en) | Multifunctional recombinant antibody, and preparation method and use therefor | |
| CN111704668B (en) | anti-CCR 4 antibodies and their use in treating cancer | |
| CN112638949B (en) | anti-B7S 1 polypeptides and uses thereof | |
| JP2018505144A (en) | Anti-CXCL12 antibody molecules and uses thereof | |
| CN115368456A (en) | anti-PD-1 polypeptides and uses thereof | |
| CN116940595A (en) | anti-TIGIT antibodies and uses thereof | |
| CN115850471A (en) | Anti-human IL-2 monoclonal antibody and application thereof | |
| CN117858899A (en) | anti-CCR 8 antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |